Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)

References

• Narayanan S, Harshman LC, Srinivas S. Second-line therapies in metastatic urothelial carcinoma. Hematol Oncol Clin North Am. 2015;29(2):341–359. doi:10.1016/j.hoc.2014.10.007
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines for Bladder Cancer V3.2019. Clinical practice guidelines in oncology: bladder cancer version 3.2019. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. NCCN.org. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed May 9, 2019.
   Google Scholar
• NCCN Guidelines for Bladder Cancer V6.2020. Clinical practice guidelines in oncology: bladder cancer version 6.2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed August 19, 2020.
   Google Scholar
• Bukhari N, Al-Shamsi HO, Azam F. Update on the Treatment of Metastatic Urothelial Carcinoma. Scientific World Journal. 2018;2018:1–7. doi:10.1155/2018/5682078
   Google Scholar
• von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–4608. doi:10.1200/JCO.2005.07.757
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–199. doi:10.1200/JCO.2011.37.3571
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–4461. doi:10.1200/JCO.2008.20.5534
   PubMed Web of Science ®Google Scholar
• Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 2018;59(5):285–296. doi:10.4111/icu.2018.59.5.285
   PubMed Web of Science ®Google Scholar
• Di Nunno V, De Luca E, Buttigliero C, et al. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;129:124–132. doi:10.1016/j.critrevonc.2018.07.004
   PubMed Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–1505. doi:10.1002/cncr.22588
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974–1982. doi:10.1200/JCO.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Mullane SA, Werner L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015;26(4):812–817. doi:10.1093/annonc/mdv009
   PubMed Web of Science ®Google Scholar
• Faraj SF, Munari E, Guner G, et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015;85(3):703e701–706. doi:10.1016/j.urology.2014.10.020
   Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med.2020;383(13):1218-1230.doi:10.1056/NEJMoa2002788
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Orsola A, Leow JJ, Wiegel T; Group EGW. eUpdate – Bladder Cancer Treatment Recommendations; 2020. Available from: https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer/eupdate-bladder-cancer-treatment-recommendations4. Accessed August 27, 2020.
   Google Scholar
• EMD Serono Inc. and Pfizer Inc. Bavencio (avelumab) injection, for intravenous use. Prescribing Information. Rockland, MA; June 2020. Available from: https://www.emdserono.com/us-en/pi/bavencio-pi.pdf. Accessed August 20, 2020.
   Google Scholar
• ClinicalTrials.gov. A Study of Avelumab in Patients with Locally Advanced or Metastatic Urothelial Cancer (JAVELIN Bladder 100; NCT02603432); 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02603432. Accessed May 17, 2019.
   Google Scholar
• Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol. 2020;38(18_suppl):LBA1. doi:10.1200/JCO.2020.38.18_suppl.LBA1
   Web of Science ®Google Scholar
• McKesson. The US Oncology Network; 2019. Available from: https://www.usoncology.com/our-company. Accessed May 16, 2019.
   Google Scholar
• Doshi G, Bhanegaonkar A, Bharmal M, et al. Patient characteristics and treatment patterns from SPEAR-BLADDER: Study informing treatment Pathway dEcision in bladder cAnceR. Value Health. 2018;21(1):S49. doi:10.1016/j.jval.2018.04.290
   Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;10;33(17):1974–1982. doi:10.1200/JCO.2014.59.4358
   Google Scholar
• Doshi G, Bhanegaonkar A, Bharmal M, et al. SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): first- through third-line time to treatment failure in the US. J Clin Oncol. 2018;36(15_suppl):4544. doi:10.1200/JCO.2018.36.15_suppl.4544
   Web of Science ®Google Scholar
• Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008–2015. Clin Genitourin Cancer. 2018;16(6):e1171–e1179. doi:10.1016/j.clgc.2018.07.025
   PubMed Web of Science ®Google Scholar
• Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol. 2019;15(12):1323–1334. doi:10.2217/fon-2018-0654
   Web of Science ®Google Scholar
• Galsky MD, Pal SK, Lin SW, et al. Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States. Bladder Cancer. 2018;4(2):227–238. doi:10.3233/BLC-170149
   PubMed Web of Science ®Google Scholar
• Galsky MD, Pal SK, Mortazavi A, et al. Randomized double-blind Phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. J Clin Oncol. 2019;37(15_suppl):4504. doi:10.1200/JCO.2019.37.15_suppl.4504
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer (NCT02500121); 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02500121. Accessed May 17, 2019.
   Google Scholar
• Galsky MD, Mortazavi A, Milowsky MI, et al. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer. J Clin Oncol. 2020;38(16):1797–1806. doi:10.1200/JCO.19.03091
   PubMed Web of Science ®Google Scholar
• Galsky MD, Moshier E, Krege S, et al. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol. 2014;32(1):48e41–48. doi:10.1016/j.urolonc.2013.07.001
   Web of Science ®Google Scholar
• Sonpavde G, Pond GR, Fougeray R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013;63(4):717–723. doi:10.1016/j.eururo.2012.11.042
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Abe T, Ishizaki J, et al. Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan. Jpn J Clin Oncol. 2018;48(8):771–776. doi:10.1093/jjco/hyy094
   Web of Science ®Google Scholar